J2291 Injection, nafcillin sodium (baxter), 20 mg

Billable / valid for submission HCPCS Release 2026Q3

Short description: Inj, nafcillin (baxter) 20mg

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Injection, nafcillin sodium (baxter), 20 mg	yes

J2210 Injection, methylergonovine maleate, up to 0.2 mg
J2212 Injection, methylnaltrexone, 0.1 mg
J2246 Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
J2247 Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg
J2248 Injection, micafungin sodium, 1 mg
J2249 Injection, remimazolam, 1 mg
J2250 Injection, midazolam hydrochloride, per 1 mg
J2251 Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
J2252 Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
J2253 Injection, midazolam (seizalam), 1 mg
J2260 Injection, milrinone lactate, 5 mg
J2265 Injection, minocycline hydrochloride, 1 mg
J2267 Injection, mirikizumab-mrkz, 1 mg
J2270 Injection, morphine sulfate, up to 10 mg
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg
J2274 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
J2277 Injection, motixafortide, 0.25 mg
J2278 Injection, ziconotide, 1 microgram
J2280 Injection, moxifloxacin, 100 mg
J2281 Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg